NYSE: EW · Medical Devices
Edwards Lifesciences (EW) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Edwards Lifesciences (EW) at $88.12 a share. The stock last closed at $107.11, which puts the model's fair value 17.7% below the price. On the model's bands that reads as Overvalued.
Revalued . Price is the close of 16 Nov 2026. Edwards Lifesciences Corporation.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $83.19 to $88.12 (+5.9%). The stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move.
What the model makes of itThe price of $107.11 is 17.7% above it: Overvalued, on a high evidence grade.
What's nextNext report on 9 Feb 2027. Options prices imply a move of about 8% either way over the next month. On the model's Quality Momentum list since 10 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give EW?
The calibrated range for EW over 63 trading days is $97.79 to $117.86. It sits around the last close, and its width comes from the volatility that EW's own options imply (28% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $75.20 to $102.30. In 14% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Edwards Lifesciences Corporation is a global medical technology firm. It specialises in products for structural heart conditions, alongside critical care and surgical patient monitoring.
Faircurve's model put the fair value at $88.12 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $83.19, so the fair value moved +5.9%. The model gives the reason in its own words: "The stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move." The calibrated range over 63 trading days is $97.79 to $117.86, built around the price from the volatility the stock's own options imply. The range is calibrated weekly against realised prices, using 8,038 past valuations. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence High. It does not say whether the fair value is right.
The model's quality score for Edwards is 61 out of 100, a composite of six factors scored against comparable companies. The balance sheet scores 100, with net debt to EBITDA at -1.50x against a peer median of 0.60x. Earnings quality scores 79, with FCF to net income at 1.39x against a peer median of 1.13x. Stability scores 10, with EBITDA margin downside volatility at 3.6 pts over five years against a peer median of 1.6 pts. The comparable companies are Boston Scientific, GE HealthCare, Stryker, DexCom, Medtronic, Abbott and Zimmer Biomet.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does EW report earnings, and how has the stock reacted?
Edwards Lifesciences's next earnings report is scheduled for 9 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 6.4% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. EW's 30 day implied volatility works out to about 8.0% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across EW's last 8 reports, ignoring direction, was 3.3%.
What the options market has priced for a month's move in EW
How does EW score on business quality?
Edwards Lifesciences's overall quality score is 61 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 50 | 13.7%ROIC | 15.5% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 79 | 1.39xFCF / net income | 1.13x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 75 | 11.5%Revenue growth, trailing | 10.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 40 | 1.2%Net buybacks / market value | 1.6% |
| Balance sheetNet debt to EBITDA and interest coverage. | 100 | -1.50xNet debt / EBITDA | 0.60x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 10 | 3.6 ptsEBITDA margin downside volatility, 5y | 1.6 pts |
How does EW compare with similar companies?
The companies in medical devices closest to Edwards Lifesciences in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| BSX Boston Scientific Corporation | $43.69 | $52.05 | +19.1% | Undervalued |
| GEHC GE HealthCare Technologies Inc. | $82.96 | $90.14 | +8.7% | Fairly valued |
| SYK Stryker Corporation | $310.72 | $275.49 | -11.3% | Fairly valued |
| DXCM DexCom, Inc. | $81.61 | $73.84 | -9.5% | Fairly valued |
| MDT Medtronic Plc | $102.88 | $100.47 | -2.3% | Fairly valued |
| ABT Abbott Laboratories | $107.45 | $106.73 | -0.7% | Fairly valued |
| ZBH Zimmer Biomet Holdings, Inc. | $101.41 | $120.99 | +19.3% | Undervalued |
| GKOS Glaukos Corporation | $244.88 | $228.07 | -6.9% | Data under review |
What the comparable companies' multiples alone would give for EW, the peer-implied price, is $61.72 a share on this run. The fair value weighs that against the company's own multiple.
Edwards Lifesciences at a glance
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring.
- Market value
- $61.6B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $7.4B
- Consensus revenue growth, next fiscal year
- +12.3%
- Analysts with estimates
- 17
- Beta to the US market
- 0.47
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. EW was not among them.
How the fair value is worked out: the model prices Edwards Lifesciences on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for EW was $83.19. As of 14 Nov 2026 it is $88.12, a change of +5.9%. The stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Edwards Lifesciences's valuation
Is Edwards Lifesciences stock undervalued or overvalued?
On Faircurve's model, EW reads as Overvalued as of 14 Nov 2026. The model's fair value is $88.12 a share against a last close of $107.11, a gap of -17.7%.
What is EW's fair value?
$88.12 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $75.20 to $102.30.
What price range does the model give EW?
$97.79 to $117.86 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Edwards Lifesciences report earnings next?
The next report is scheduled for 9 Feb 2027. Companies can move their dates.
How much has EW moved on past earnings reports?
Across its last 8 reports the median two session move was 3.3%, ignoring direction. The largest was +6.4% around the report of 23 Apr 2025.
How confident is the model in this valuation?
The model's evidence grade for EW is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on EW
The model has an idea open on EW under Quality Momentum since 10 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on EW with their outcomes. A free account is enough.